Manuela Tiako Meyo

Manuela Tiako Meyo

Auto-generated profile, based on publicly available information

Manuela Tiako Meyo

Department of Medical Oncology, Cochin Hospital, AP-HP, CARPEM; Immunomodulatory Therapies Multidisciplinary Study Group (CERTIM), Paris, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2020 in Cancers
Verified
Journal Article
Open access
PDF file
MMManuela Tiako Meyo
Manuela Tiako Meyo
AJAnne Jouinot
Anne Jouinot
ELEtienne Giroux Leprieur
Etienne Giroux Leprieur
Elizabeth FabreElizabeth Fabre
Elizabeth Fabre
MWMarie Wislez
Marie Wislez
Benoit BlanchetBenoit Blanchet
Benoit Blanchet
A large interindividual variability has been observed in anti Programmed cell Death 1 (anti-PD1) therapies efficacy. The aim of this study is to assess the correlation of soluble PD-1 (sPD-1), soluble Programmed cell Death Ligand 1 (sPD-L1), Vascular Endothelial Growth Factor A (VEGFA), soluble CD40 ligand (sCD40L) and soluble CD44 (sCD44), with survival in nivolumab-treated metastatic non-small cell lung cancer (NSCLC) patients. Plasma biomarkers were assayed at baseline and after two cycles of nivolumab. A cut-off of positivity for sPD-1, sPD-L1 and sCD40L expressions was defined as a plasma level above the lower limit of quantification. Baseline sPD-1 and sPD-L1 levels were subsequently analyzed in a control group of EGFR-mutated (Epidermal Growth Factor Receptor) NSCLC patients. Association between survival and biomarkers was investigated using Cox proportional hazard regression model. Eighty-seven patients were included (51 nivolumab-treated patients, 36 in EGFR-mutated group). In nivolumab group, baseline sPD-1, sPD-L1 and sCD40L were positive for 15(29.4%), 27(52.9%) and 18(50%) patients, respectively. We defined a composite criteria (sCombo) corresponding to sPD-1 and/or sPD-L1 positivity for each patient. In nivolumab group, baseline sCombo positivity was associated with shorter median progression-free survival (PFS) (78 days 95%CI (55–109) vs. 658 days (222-not reached); HR: 4.12 (1.95–8.71), p = 0.0002) and OS (HR: 3.99(1.63–9.80), p = 0.003). In multivariate analysis, baseline sCombo independently correlated with PFS (HR: 2.66 (1.17–6.08), p = 0.02) but not OS. In EGFR-mutated group, all patients were baseline sCombo positive; therefore this factor was not associated with survival. After two cycles of nivolumab, an increased or stable sPD-1 level independently correlated with longer PFS (HR: 0.49, 95%CI (0.30–0.80), p = 0.004) and OS (HR: 0.39, 95%CI (0.21–0.71), p = 0.002). VEGFA, sCD40L and sCD44 did not correlate with survival. We propose a composite biomarker using sPD-1and sPDL-1 to predict nivolumab efficacy in NSCLC patients. A larger validation study is warranted.

6 September 2024 in Clinical Nutrition ESPEN
Verified
Journal Article
Closed access
MMManuela Tiako Meyo
Manuela Tiako Meyo
PBPascaline Boudou-Rouquette
Pascaline Boudou-Rouquette
JAJennifer Arrondeau
Jennifer Arrondeau
JCJeanne Qiong Yu Chen
Jeanne Qiong Yu Chen
LHLaure Hirsch
Laure Hirsch
FGFrançois Goldwasser
François Goldwasser